Associate Professor Gantier is a research group leader, working at the Hudson Institute of medical research in Melbourne, Australia. 

The central aim of A/Prof Gantier’s research is to define how nucleic acids (DNA and RNA) modulate immune responses, and how this can be leveraged to develop novel therapies to treat cancer and auto-inflammation.

Over the past decade his research has significantly advanced our understanding of Toll-Like receptor 7 and 8 sensing of RNAs, and cGAS-STING detection of damaged DNA. His laboratory is currently studying next generation TLR7/8 agonists and inhibitors with can be used to improve mRNA-based vaccinations, along with cGAS/STING inhibitors to treat auto-inflammatory (such as lupus) and hyper-inflammatoy disorders.

In addition, Dr Gantier has made important findings regarding how a class of endogenous small RNAs, known as microRNAs, persist in cells to regulate inflammation. This has led to the identification of microRNA sequence variations, which control microRNA stability and could be used as novel disease biomarkers.